In the BioHarmony Drug Report Database

"Preview" Icon

Ingenol mebutate

Picato (ingenol mebutate) is a small molecule pharmaceutical. Ingenol mebutate was first approved as Picato on 2012-01-23. It is used to treat actinic keratosis in the USA. The pharmaceutical is active against protein kinase C delta type. In addition, it is known to target protein kinase C epsilon type, protein kinase C alpha type, protein kinase C gamma type, and protein kinase C beta type. Picato’s patents are valid until 2033-05-15 (FDA).

 

Trade Name

 

Picato
 

Common Name

 

ingenol mebutate
 

ChEMBL ID

 

CHEMBL1863513
 

Indication

 

actinic keratosis
 

Drug Class

 

Image (chem structure or protein)

Ingenol mebutate structure rendering